anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The incidence and severity of proteinuria was higher in patients receiving bevacizumab as compared to patients receiving chemotherapy. Grade 3 (defined as urine dipstick 4+ or > 3.5 grams of protein per 24 hours) to Grade 4 (defined as nephrotic syndrome) ranged from 0.7% to 7% in clinical studies. The overall incidence of proteinuria (all grades) was only adequately assessed in Study BO17705, in which the incidence was 20%. Median onset of proteinuria was 5.6 months (15 days to 37 months) after initiating bevacizumab. Median time to resolution was 6.1 months (95% CI: 2.8, 11.3). Proteinuria did not resolve in 40% of patients after median follow-up of 11.2 months and required discontinuation of bevacizumab in 30% of the patients who developed proteinuria [see Adverse Reactions (6.1)].

In an exploratory, pooled analysis of patients from seven randomized clinical studies, 5% of patients receiving bevacizumab with chemotherapy experienced Grades 2-4 (defined as urine dipstick 2+ or greater or > 1 gram of protein per 24 hours or nephrotic syndrome) proteinuria. Grades 2-4 proteinuria resolved in 74% of patients. Bevacizumab was reinitiated in 42% of patients. Of the 113 patients who reinitiated bevacizumab, 48% experienced a second episode of Grades 2-4 proteinuria.

Nephrotic syndrome occurred in < 1% of patients receiving bevacizumab across clinical studies, in some instances with fatal outcome. In a published case series, kidney biopsy of 6 patients with proteinuria showed findings consistent with thrombotic microangiopathy. Results of a retrospective analysis of 5805 patients who received bevacizumab with chemotherapy and 3713 patients who received chemotherapy alone, showed higher rates of elevated serum creatinine levels (between 1.5 to 1.9 times baseline levels) in patients who received bevacizumab. Serum creatinine levels did not return to baseline in approximately one-third of patients who received bevacizumab.

Monitor proteinuria by dipstick urine analysis for the development or worsening of proteinuria with serial urinalyses during MVASI therapy. Patients with a 2+ or greater urine dipstick reading should undergo further assessment with a 24-hour urine collection. Withhold for proteinuria greater than or equal to 2 grams per 24 hours and resume when less than 2 grams per 24 hours. Discontinue in patients who develop nephrotic syndrome.

Data from a postmarketing safety study showed poor correlation between UPCR (Urine Protein/Creatinine Ratio) and 24-hour urine protein [Pearson Correlation 0.39 (95% CI: 0.17, 0.57)].
Tonsillectomy is common procedure associated with significant post-operative pain typically managed by narcotic pain medication. Narcotics, however, can have inherent unwanted side effects such as respiratory depression. In fact, a recent U.S. Food and Drug Administration (FDA) warning has reported deaths from respiratory distress that were associated with use of codeine in children after tonsillectomy. Finding alternative pain management regimens therefore is essential in post-tonsillectomy care. Non-steroidal anti-inflammatory (NSAID) medications may provide an effective alternative to narcotics, but use of NSAIDs routinely after tonsillectomy has been limited due to concern for theoretical increased risk of post-operative bleeding, This is likely true for NSAIDs such as aspirin. NSAIDs such as ibuprofen, however, are believed to have no greater risk of bleeding than baseline, but this has not been proven. Recent, well-designed, prospective pediatric studies have demonstrated effective analgesia improvement with the addition of non-steroidal anti-inflammatory drugs such as ibuprofen to post-operative pain management regimens, and no increased rate of post-surgery bleeding. This has not adequately been studied in adults but could provide many patients significant pain relief in the post-operative period if it is shown to not increase post tonsillectomy hemorrhage rates, as already demonstrated in the pediatric population.
Low- and middle-income countries (LMICs) bear most of the global burden of critical illness. Managing this burden requires improved understanding of epidemiology and outcomes in LMIC intensive care units (ICUs), including LMIC-specific mortality prediction scores. This study was a retrospective observational study at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia, examining all consecutive medical ICU admissions from June 2014 to April 2015. The primary outcome was ICU mortality; secondary outcomes were prolonged ICU stay and prolonged mechanical ventilation. ICU mortality prediction models were created using multivariable logistic regression and compared with the Mortality Probability Model-II (MPM-II). Associations with secondary outcomes were examined with multivariable logistic regression. There were 198 admissions during the study period; mortality was 35%. Age, shock on admission, mechanical ventilation, human immunodeficiency virus, and Glasgow Coma Scale ≤8 were associated with ICU mortality. The receiver operating characteristic curve for this 5-factor model had an AUC of 0.8205 versus 0.7468 for MPM-II, favoring the simplified new model. Mechanical ventilation and lack of shock were associated with prolonged ICU stays. Mortality in an LMIC medical ICU was high. This study examines an LMIC medical ICU population, showing a simplified prediction model may predict mortality as well as complex models.
Only those who opt in to group support will be invited and allocated into treatment groups at random. Participants in this arm will be invited to 9 weekly ACT-informed therapy sessions involving core values identification, mindfulness practices and committed action plans. There will be homework in between sessions.
The present invention relates to methods and compositions to treat subjects having cystic fibrosis. These compositions comprise the class of isothiocyanates. Isothiocyanates, absorbed by a cell are conjugated with glutathione GSH by glutathione-s-tranferase (GST). The conjugates are substrates of the multi-drug resistance associated (MRP)/multi-drug resistance (MDR) proteins. These proteins are functionally redundant to the cystic fibrosis transmembrane conductance regulator (CFTR), allowing for the substrate conjugates to be exported from the cell. The export of GSH conjugates restores intracellular and extracellular levels of GSH to normal levels. Normalizing both extracellular and intracellular GSH via the increased conjugation of isothiocyanates with GSH, and subsequent export, can significantly rectify numerous enzymatic processes and correct the pathologies that are typical of patients suffering from cystic fibrosis.
A liquid dispersible powder comprising nanoscale grains of a matrix material containing one or more isolated nanoparticles is provided. A composition for the magnetic nanoparticle hyperthermia (MNH) treatment of tumours comprising nanoscale grains of a matrix material containing one or more isolated nanoparticles is also outlined. Preferably the nanoparticles are around 15nm in size. Preferably at least a portion of the nanoparticles comprise magnetic nanoparticles of a magnetic core selected from one or more of iron or an alloy of iron and cobalt encased in a biocompatible shell which may be an FeO shell. A method of production of a liquid-dispersible powder comprising the steps of: (a) providing nanoparticles prepared under ultra-high vacuum (UHV) gas phase conditions; (b) co-depositing the nanoparticles within a matrix material under UHV gas phase conditions; and (c) grinding the film to a fine powder comprising grains of groups of matrix isolated nanoparticles, is provided. Preferably the grinding step comprises ball milling.
Despite continued improvements in medical therapy, mortality from septic shock has remained between 30% and 70% for the past three decades with only a slight decrease in mortality rate. Standard treatment of septic shock is fluid resuscitation, followed by agents with vasopressor activity to correct hypotension in septic shock. The question rises whether vasopressors should be the first line of action in septic shock Opening and recruiting the microcirculation are expected to improve regional organ function and tissue distress in severe sepsis. Beside fluid resuscitation, vasodilatation, in this respect, enhances microcirculatory flow while vasoconstriction causes a reduction in microcirculatory flow. On the other hand, a minimal perfusion pressure should be present. Our aim is to asses the effects of two resuscitation protocols in severe sepsis: the "standard treatment" using predefined pressure goals versus a microcirculation guided therapy.
The invention discloses an extract of agrimony total flavonoids and an extraction and preparation method thereof; the total amount of ketosteroid compounds accounts for 25 percent to 100 percent of the total extraction matter. The invention takes agrimony as raw material and organic solvent whether containing or not containing water as extraction solvent. The extraction procedure is as following: extracting, leaching with solvent and adsorbing resin column to make purification process or using inorganic acid to regulate the PH value of concentrated solution to be no higher than 3, and then obtaining the extraction matter of agrimony after processing. Experiments prove that the extraction matter of agrimony total flavonoids has functions of antioxidation, anti-myocardial ischemia and reducing blood lipid. The extraction matter of agrimony total flavonoids can be used as food preservative and health product additive; the extraction matter of agrimony total flavonoids, carriers acceptable in pharmacy or excipient are made into various pharmaceutical dosage forms for anti-myocardial ischemia and reducing blood lipid. The invention has the advantages of simple technics and good treatment effect and can be widely used for curing or preventing coronary heart disease, hyperlipoidemia, high blood pressure or preventing cardio-cerebrovascular diseases such as atherosclerosis, etc.
In a randomized fashion, the MSCs, in the appropriate dose, will be shipped to the performance site where the MSCs will be thawed, diluted and administered. The thawed MSCs with be administered within 4 hours to subjects in a monitored setting with telemetry and pulse oximetry. Patients will be premedicated with hydrocortisone and diphenhydramine. All subjects will be monitored throughout the infusion procedure with vital signs and pulse oximetry at 15 minutes prior to infusion and ending 2 hours post procedure. They will also be evaluated for clinical signs of pulmonary distress. Subjects will be discharged 2 hours post-infusion if no signs of complications.
Liposomes in uni- or multi lamella form contain (A) steryl glucoside e.g. beta-sitosteryl- beta-D-cholesteryl- beta-D-glucoside; and/or (B) steryl glucoside monopalmitate, e.g., as active ingredient(s). Active ingredients are pref. contained in lipids, partic. a natural phosphatidyl choline, e.g., egg yolk lecitin, or a synthetic phosphatidyl choline e.g., dimyristoyl phosphatidyl choline, dipalmitoyl phosphatidyl choline, distearyl phosphatidyl choline or dioleyl phosphatidyl choline. By using a small amt. of a lipid, the active ingredients can be formulated into intravenously injectable prepns. having a high content of the active ingredients and exhibiting improved pharmacological effects.
Patients with functional dyspepsia and normal gastric emptying. All patients in trial will be giving themselves vagal nerve stimulation for two minutes on each side twice a day in the morning and the night for four weeks starting at visit 3 and ending at visit 5.
BACKGROUND: Abiraterone acetate (AA) is used in treatment of patients with metastatic prostate cancer. Despite the survival advantage, AA is associated with hypertension due to mineralocorticoid excess syndrome.
OBJECTIVE: We conducted a single-center retrospective analysis to evaluate the real-world incidence and severity of AA-induced hypertension.
METHODS: Electronic health records were used to collect baseline characteristics and prostate cancer history. Patient data, including blood pressure at each 4 (±2)-week interval, were collected for 24 weeks after the initiation of AA therapy. The primary endpoint was the incidence and severity of AA-induced hypertension. The secondary endpoints include effect of different prednisone dosing regimens and prostate cancer types on hypertensive incidence and the impact of clinical pharmacists' involvement in managing AA-induced hypertension.
RESULTS: A total of 142 patients who met our inclusion criteria received AA for metastatic prostate cancer, 73 (51.4%) with metastatic castration-resistant prostate cancer (mCRPC), and 69 (48.6%) with metastatic castration-sensitive prostate cancer (mCSPC). Of all, 43.7% experienced all-grade hypertension, and 28.2% experienced grade 3-4 hypertension. There was no difference in incidence of hypertension between patients receiving 5 mg of prednisone daily and those receiving 5 mg of prednisone twice daily. All-grade hypertension occurred in 39.7% of mCRPC and 47.8% of mCSPC patients (P = 0.33). Thirty-two percent of patients were actively managed by a clinical pharmacist and had an overall trend of reduced hypertension severity after 12 weeks.
CONCLUSION AND RELEVANCE: This single-center, retrospective cohort study found that real-world metastatic prostate cancer patients who received AA had substantially higher incidence and severity of hypertension compared with clinical trials regardless of prednisone dose. In patients with mCRPC and mCSPC, the role of prednisone dose in hypertension incidence and severity warrants further investigation. Overall, results indicate the need for closely monitoring hypertension and optimization of anti-hypertensive therapy by multidisciplinary teams in metastatic prostate cancer patients receiving AA.
Patients previously randomized into the DiVA Sham and IntraGen Sham groups will be placed in the Dual Treatment group. Patients will have a total of 3 dual treatments, spaced 1 month apart. Each treatment will last approximately 20 minutes. Prior to dual treatments, the Zimmern probe will be used to measure vaginal wall elasticity and a 0.33mm biopsy will be taken. At each visit, the Zimmern probe will be used. Biopsies will be taken at follow up visits.
Inclusion criteria: Aged over 18, confirming RA for more than 6 months Exclusion criteria. Patients with Chinese reading comprehension barriers (unable to complete the questionnaire independently), without any RA treatment The Treatment Satisfaction Questionnaire for Medication (TSQM-II) will be used in patients.
Obesity and related comorbidities have negative impacts on cognitive function. Weight loss seems to be associated with the improvement of cognitive function and the recovery of brain structure, but the underlying mechanism is not clear. This meta-analysis aimed to explore the status of cognitive function including memory, executive function, attention and language ability in patients with obesity, and to further investigate whether bariatric surgery can improve overall cognitive function in these patients. A total of 11 literatures with 728 subjects were included after retrieval and exclusion. The meta-analysis showed significant improvements in memory, attention and executive function scores after undergoing bariatric surgery in the patients with obesity. However, there was no significant improvement in language ability.
The invention belongs to the technical field of Chinese herbal medicine atomization products, and discloses a herbal atomization composition beneficial to breath freshening and a preparation method thereof. The composition is prepared from pure plant Chinese herbal medicines. The main taste is sweet and sour, and the nature is mild; the lung and stomach meridians are the channels of herbs. The ageratum is fragrant and turbid, and sterilized; the mint can soothe liver and promote qi circulation; the chrysanthemum disperses wind-heat; honeysuckle is anti-inflammatory; chicory induces diuresis to reduce edema; perilla frutescens has the effects of relieving exterior syndrome and dispelling cold; purslane has the functions of clearing away heat and toxic materials; the Chinese olive can relieve sore throat; semen Scaphii Lychnophori has effects in clearing lung-heat and eliminating phlegm; semen Ginkgo has effects of astringing lung and relieving asthma; the cordate houttuynia can induce diuresis for treating stranguria; the lucid ganoderma has the effects of tonifying qi and soothing nerves; sea-buckthorn can invigorate the spleen to promote digestion. The above formula is an integral formula, and the formula has effects of invigorating stomach, resolving food stagnation, relieving swelling, promoting fluid production, dispersing stagnated liver qi, activating qi-flowing, dispelling pathogenic wind and heat, clearing heat, detoxicating, clearing lung-heat, and relieving sore throat. By adding a large amount of mint, the use feeling is improved, the safety is realized, and the discomfort cannot occur.
All patient participants will receive text messages advising how to access their study A1c test results, and receive high-quality print materials including a book upon enrollment and quarterly newsletters on healthy living with diabetes. All support person participants will receive high-quality print materials including a book and information about providing quality social support upon enrollment and quarterly newsletters on healthy living with diabetes.
Patients referring for orthodontic consultation at the Unit of Orthodontics and Pediatric Dentistry, Section of Dentistry, Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy, will be enrolled for the study according to the inclusion criteria. For each patient, lateral cephalometric radiograph and panoramic radiograph will be performed. For each lateral cephalometric radiograph, a cephalometric tracing will be performed with DeltaDent software (version 2.5.12, Outside Format, Pandino, Italy). Riedel's ANB angle \[Riedel 1952\] has been chosen to determine patients' skeletal class. Steiner's SN\^GoGn angle \[Steiner 1953\] has been chosen to evaluate skeletal divergence. Facial axis (BaNa\^CCGn), Lower Facial Height (LFH) and mandibular plan angle (FH\^GoMe) from Rickett's analysis \[Rickett's 1961\] have been adopted to determine facial growth. According to Jaraback's cephalometric analysis \[Jaraback 1985\], saddle angle, articular angle, upper gonial angle, lower gonial angle will be measured to assess the growth pattern. Linear measurements of sella depth, sella diameter and interclinoid distance \[Silverman 1957; Kisling 1966\] will be calculated. Linear regressions between craniofacial patterns, sella turcica bridging and third molar agenesis will be calculated. A control group with no third molar agenesis will be provided.
The annual American Heart Association (AHA) and National Institutes of Health statistical report details the most up to date statistics related to heart disease, stroke and cardiovascular risk factors, primarily within the USA. Although not a formal systematic review or meta-analysis, this 600 page report provides the most comprehensive and best summary of cardiovascular statistics for the year in question. Although data are collated from USA data registries, it serves as a critical resource for clinicians, policymakers, administrators and researchers in the northern and southern hemispheres. In this special report, we have chosen to highlight aspects of the document that are relevant to nephrologists, given the overlap of cardiovascular and renal disease. These include (i) key and emerging cardiovascular data signals in the general and chronic kidney disease (CKD) populations, (ii) ethnic and socio-economic disparity, (iii) environmental and behavioural factors that drive high levels of cardiovascular disease and which are key components of the AHA's eight components of the Life Essential cardiovascular health score, and (iv) the impact of COVID-19 both directly and indirectly on heart health. We provide some commentary and critical analysis of both the data and of the production of such data sets suggesting that similar data on CKD could also be published and linked to the AHA and other datasets.
Acute overdose exceeding 0.5 mg/kg (35 mg for a 70 kg average adult) is usually fatal. Fatalities have been reported with as little as 7 mg.

  
Symptoms: Colchicine poisoning presents in three sequential and usually overlapping phases. The first stage of acute colchicine toxicity typically occurs within 24 hours of ingestion and includes gastrointestinal symptoms such as abdominal pain, nausea, vomiting, and diarrhea, and significant fluid loss, leading to volume depletion. Peripheral leukocytosis may also be seen. The second stage develops 24 to 72 hours after ingestion and is characterized by multi-organ failure. Death is usually a result of respiratory depression and cardiovascular collapse. Recovery may be accompanied by rebound leukocytosis about one week after the initial ingestion. 

  
Treatment: No specific antidote is known. Elimination of toxins by gastric lavage followed by activated charcoal should be attempted within 1-2 hours of ingestion. Colchicine is not effectively removed by hemodialysis.
### Dosing in Elderly Patients

Due to a decrease in unbound clearance of valproate and possibly a greater sensitivity to somnolence in the elderly, the starting dose should be reduced in these patients. Starting doses in the elderly lower than 250 mg can only be achieved by the use of divalproex sodium delayed-release tablets. Dosage should be increased more slowly and with regular monitoring for fluid and nutritional intake, dehydration, somnolence, and other adverse reactions. Dose reductions or discontinuation of valproate should be considered in patients with decreased food or fluid intake and in patients with excessive somnolence. The ultimate therapeutic dose should be achieved on the basis of both tolerability and clinical response [see Warnings and Precautions (5.12)].

### Dose Related Adverse Reactions

The frequency of adverse effects (particularly elevated liver enzymes and thrombocytopenia) may be dose related. The probability of thrombocytopenia appears to increase significantly at total valproate concentrations of ≥ 110 mcg/mL (females) or ≥ 135 mcg/mL (males) [see Warnings and Precautions (5.6)]. The benefit of improved therapeutic effect with higher doses should be weighed against the possibility of a greater incidence of adverse reactions.

### G.I. Irritation

Patients who experience G.I. irritation may benefit from administration of the drug with food or by slowly building up the dose from an initial low level.